Smart-Nuclide Biotech

Smart-Nuclide Biotech is a clinical-stage biopharmaceutical company specializing in the development of innovative radiopharmaceuticals for cancer diagnosis and therapy. The company leverages its proprietary single-domain antibody (nanobody) platform to create targeted radioligands with optimized pharmacokinetics, enabling rapid tumor penetration and fast systemic clearance. Their pipeline includes both diagnostic imaging agents and therapeutic radiopharmaceuticals targeting well-validated oncology markers such as PD-L1 and FAP. By integrating precision medicine with nuclear medicine, Smart-Nuclide aims to provide more effective 'theranostic' solutions for patients with various solid tumors.